Phytopharm Share Discussion Threads

[enigma2002] 16/1/2012 09:21

getting there slowly but surely... the talk of renewed interest in Hoodia is particularly encouraging - weight loss, afterall, is an enormous market these results on top all add up to a good thing :D.

[ferdy1] 16/1/2012 08:24

Mr Tim Sharpington, CEO, Phytopharm, said, "These results are very encouraging as we set a difficult challenge in this study by looking for efficacy in a severe, end-stage disease model. We have established an impressive set of data for Cogane(TM) in a broad range of neurodegenerative disease models, including Parkinson's and Alzheimer's disease as well as ALS. There is a major unmet need and substantial commercial opportunity for new therapies which can delay or halt the progression of these diseases. We look forward to receiving more data on Cogane(TM) as we complete our ongoing clinical study in Parkinson's disease."

[ferdy1] 16/1/2012 08:01

Great result today MrsA ?

[baldeagle5] 08/1/2012 14:07

This is our month methinks Mrs Ape...!

[mrsapeslaptop] 08/1/2012 09:38

and the tantalsing prospect of being able to use cogane after phase II data, avoiding the need for a partner for phase III

[mrsapeslaptop] 07/1/2012 11:05

here is the link

[ferdy1] 06/1/2012 08:21

MrsApeslaptop

Thank you

[mrsapeslaptop] 05/1/2012 19:01

on the MND website research section.

the research is due to be complete in Jan

[ferdy1] 05/1/2012 13:51

Hi MrsApeslaptop

Why do you say Jan and not Q1?

Thanks



- 23 Dec'11 - 12:14 - 124 of 126

ALS news will be interesting

due in January.

[mrsapeslaptop] 23/12/2011 12:14

ALS news will be interesting

due in January.
The only existing treatment has a marginal impact. and is Riluzole marketed by Sanofi-Aventis.

They would be the obvious choice to fund a Phase II trial, and orphan status is in place.

Happy Xmas everyone

[madmonkflin] 22/12/2011 22:23

that sounds positive if they're talking about phase iii but i cant see how that will go ahead unless they have positive results and that was something like achieving a 40% improvement compared to those who werent on cogane.

[mrsapeslaptop] 22/12/2011 10:17

placebo plus 3 doses in the trial.
phase 3 being mooted. the first tranches of recruits are finishing their trial and results being unblinded.
plus ALS & Glaucoma news next qtr. could be an explosive few months

[madmonkflin] 21/12/2011 22:35

slightly bloody worrying reading unless both those guys are on placebos as the phase i trials showed immediate and increasing effect on the macaque monkeys, so i can't say it sounds good if they aren't noticing any effects.

[mrsapeslaptop] 21/12/2011 18:24

licence deal = years peak revenues
>$2Bn market with no disease mofifying treatment available
over a quid IMHO

[baldeagle5] 21/12/2011 17:27

Interesting link missusA.
What do you expect to occur if Phase 2 is positive share price wise?

[mrsapeslaptop] 20/12/2011 16:28

looks like they are looking for hoodia licencees again. we still get a percentage

[madmonkflin] 12/12/2011 11:16

1.8m shares?

[madmonkflin] 12/12/2011 08:59

surprised so far that its moved over the last week or so and after a fairly uneventful rns. but looking forward to ALS in Jan (even though it was touted as a Q4 finish) and Parkinsons trials finish in the Spring so lets hope they speed up the conclusion on that.

[mrsapeslaptop] 11/12/2011 23:59

its very dull talking to oneself.

but. The orphan drug status (reduced costs & timescale to market).
the govt pulling revenues forward a year (treatements available before P4 completed)

and 3 markets with no current disease modifying treatments.

we may see 20 p to 50 p before the end of Jan.
gla (but talking to myself and mad monk).

I wasnt expecting a big move on this for a year. but ready to be pleasantly surprised ( & retire)

[mrsapeslaptop] 07/12/2011 21:33

yes but nowt in comparison

[multibagger] 07/12/2011 09:24

Mrsape,

Thought you held SLN as well ?